ESTROGEN-RECEPTOR, PROGESTERONE-RECEPTOR, PS2, ERD5, HSP27 AND CATHEPSIN-D IN INVASIVE DUCTAL BREAST CARCINOMAS

被引:59
作者
HURLIMANN, J [1 ]
GEBHARD, S [1 ]
GOMEZ, F [1 ]
机构
[1] UNIV LAUSANNE,DEPT MED,DIV ENDOCRINOL & BIOCHIM CLIN,CH-1011 LAUSANNE,SWITZERLAND
关键词
BREAST CANCER; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PS2; HSP27; ERD5; CATHEPSIN-D;
D O I
10.1111/j.1365-2559.1993.tb01196.x
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Hormonal receptors and markers for prognostic evaluation were detected immunohistochemically in 196 infiltrating ductal breast carcinomas. Immunohistochemical detection of progesterone and oestrogen receptor is a method giving results generally concordant with those of the binding assay. However, immunohistochemical detection seems better. It allows the detection of hormonal receptors on small carcinomas, it is not modified by the endogenous hormones, and it has a slightly better correlation with prognosis and with the response to hormone therapy. Immunohistochemical detection of progesterone receptor has a prognostic value, sorting a negative subgroup with a poor prognosis from the oestrogen receptor positive tumours. These results can be obtained without quantitative immunohistological methods. ERD5, pS2, HSP27 and cathepsin D are associated with oestrogen receptor positivity. pS2 and HSP27 are interesting markers. They characterize a subgroup of oestrogen receptor negative tumours with a good prognosis. Moreover, pS2 is a marker of response to hormone therapy. ERD5 and cathepsin D do not appear to be of value as markers of prognosis.
引用
收藏
页码:239 / 248
页数:10
相关论文
共 50 条
[1]  
ADAMS DJ, 1985, CANCER RES, V45, P2445
[2]   IMMUNOCYTOCHEMICAL DETERMINATION OF THE ESTROGEN-REGULATED PROTEIN MR-24,000 IN PRIMARY BREAST-CANCER AND RESPONSE TO ENDOCRINE THERAPY [J].
ANDERSEN, J ;
SKOVBON, H ;
POULSEN, HS .
EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1989, 25 (04) :641-643
[3]  
BERGER U, 1989, CANCER RES, V49, P5176
[4]   HISTOLOGICAL GRADING AND PROGNOSIS IN BREAST CANCER - A STUDY OF 1409 CASES OF WHICH 359 HAVE BEEN FOLLOWED FOR 15 YEARS [J].
BLOOM, HJG ;
RICHARDSON, WW .
BRITISH JOURNAL OF CANCER, 1957, 11 (03) :359-&
[5]   QUALITY-CONTROL IN IMMUNOCYTOCHEMISTRY - EXPERIENCES WITH THE ESTROGEN-RECEPTOR ASSAY [J].
BOSMAN, FT ;
DEGOEIJ, AFPM ;
ROUSCH, M .
JOURNAL OF CLINICAL PATHOLOGY, 1992, 45 (02) :120-124
[6]  
CHARPIN C, 1988, CANCER RES, V48, P1578
[7]   COLOCALIZATION OF ESTROGEN AND PROGESTERONE RECEPTORS WITH AN ESTROGEN-REGULATED HEAT-SHOCK PROTEIN IN PARAFFIN SECTIONS OF HUMAN BREAST AND ENDOMETRIAL CANCER-TISSUE [J].
CIOCCA, DR ;
STATI, AO ;
DECASTRO, MMA .
BREAST CANCER RESEARCH AND TREATMENT, 1990, 16 (03) :243-251
[8]  
COFFER AI, 1985, CANCER RES, V45, P3686
[9]   COMPARISON OF MONOCLONAL IMMUNOCYTOCHEMICAL AND IMMUNOENZYMATIC METHODS FOR STEROID-RECEPTOR EVALUATION IN BREAST-CANCER [J].
DENEGRI, F ;
CAMPANI, D ;
SARNELLI, R ;
MARTINI, L ;
GIGLIOTTI, A ;
BONACCI, R ;
FABBRI, R ;
SQUARTINI, F ;
PINCHERA, A ;
GIANI, C .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1991, 96 (01) :53-58
[10]  
DOMAGALA W, 1992, AM J PATHOL, V141, P1003